Cargando…

Health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia

BACKGROUND: Febrile neutropenia associated with some chemotherapy regimens can lead to potentially fatal complications and high health care costs. Administration of pegfilgrastim using an On-Body Injector (OBI) may be more convenient for cancer patients and physicians in countries with limited acces...

Descripción completa

Detalles Bibliográficos
Autores principales: Larrarte-González, María Alejandra, Pineda-Posada, Mariana, Gaitán, Álvaro Andrés, Amaya-Amaya, Jenny, Ojeda, Kelman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207821/
https://www.ncbi.nlm.nih.gov/pubmed/37221537
http://dx.doi.org/10.1186/s12913-023-09454-z
_version_ 1785046538581442560
author Larrarte-González, María Alejandra
Pineda-Posada, Mariana
Gaitán, Álvaro Andrés
Amaya-Amaya, Jenny
Ojeda, Kelman
author_facet Larrarte-González, María Alejandra
Pineda-Posada, Mariana
Gaitán, Álvaro Andrés
Amaya-Amaya, Jenny
Ojeda, Kelman
author_sort Larrarte-González, María Alejandra
collection PubMed
description BACKGROUND: Febrile neutropenia associated with some chemotherapy regimens can lead to potentially fatal complications and high health care costs. Administration of pegfilgrastim using an On-Body Injector (OBI) may be more convenient for cancer patients and physicians in countries with limited access to high-complexity healthcare. This study aims to describe physician and nurse preferences regarding different options for administration of pegfilgrastim at cancer centers, the chemotherapy schemes for which pegfilgrastim is most frequently prescribed and how healthcare providers prioritize certain administration schemes according to patients’ access to healthcare services. METHODS: Observational, descriptive, cross-sectional study and survey, conducted between 2019 and 2020, to describe physician and nurse preferences regarding options for administration of pegfilgrastim at cancer centers, the demographics of the study population and characteristics of participating cancer centers. It included 60 healthcare professionals practicing at oncology centers from 8 cities in Colombia who were contacted and surveyed via telephone. Quantitative continuous variables were summarized using central tendency and dispersion measures. RESULTS: It was found that 35% of participants are haemato-oncologists, oncologists or hematologists, 30% are general practitioners, and 35% are other healthcare professionals (i.e., nurse, oncology nurse and head nurse). Our study shows that 48% of physicians prefer the use of OBI, particularly in the scheme of 24 h after myelosuppressive chemotherapy administrations. Regardless of patient frailty and travel time to the clinic, over 90% of healthcare providers (HCPs) prefer to prioritize preventing the patient from having to return to the clinic for pegfilgrastim administration as well as to increase healthcare staff availability through the use of OBI. CONCLUSIONS: The present study is the first one in Colombia that sought the reasons behind HCPs’ choice to use OBI pegfilgrastim. Our results indicate that most professionals prefer to avoid the patient having to re-enter the care center for pegfilgrastim administration to facilitate access to healthcare for patients; patient characteristics and ease of transport are determining factors for respondents when choosing an option for drug administration. We found OBI is the preferred alternative by most HCPs and a good resource optimization strategy in the context of cancer patients’ health care in Colombia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-023-09454-z.
format Online
Article
Text
id pubmed-10207821
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102078212023-05-25 Health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia Larrarte-González, María Alejandra Pineda-Posada, Mariana Gaitán, Álvaro Andrés Amaya-Amaya, Jenny Ojeda, Kelman BMC Health Serv Res Research BACKGROUND: Febrile neutropenia associated with some chemotherapy regimens can lead to potentially fatal complications and high health care costs. Administration of pegfilgrastim using an On-Body Injector (OBI) may be more convenient for cancer patients and physicians in countries with limited access to high-complexity healthcare. This study aims to describe physician and nurse preferences regarding different options for administration of pegfilgrastim at cancer centers, the chemotherapy schemes for which pegfilgrastim is most frequently prescribed and how healthcare providers prioritize certain administration schemes according to patients’ access to healthcare services. METHODS: Observational, descriptive, cross-sectional study and survey, conducted between 2019 and 2020, to describe physician and nurse preferences regarding options for administration of pegfilgrastim at cancer centers, the demographics of the study population and characteristics of participating cancer centers. It included 60 healthcare professionals practicing at oncology centers from 8 cities in Colombia who were contacted and surveyed via telephone. Quantitative continuous variables were summarized using central tendency and dispersion measures. RESULTS: It was found that 35% of participants are haemato-oncologists, oncologists or hematologists, 30% are general practitioners, and 35% are other healthcare professionals (i.e., nurse, oncology nurse and head nurse). Our study shows that 48% of physicians prefer the use of OBI, particularly in the scheme of 24 h after myelosuppressive chemotherapy administrations. Regardless of patient frailty and travel time to the clinic, over 90% of healthcare providers (HCPs) prefer to prioritize preventing the patient from having to return to the clinic for pegfilgrastim administration as well as to increase healthcare staff availability through the use of OBI. CONCLUSIONS: The present study is the first one in Colombia that sought the reasons behind HCPs’ choice to use OBI pegfilgrastim. Our results indicate that most professionals prefer to avoid the patient having to re-enter the care center for pegfilgrastim administration to facilitate access to healthcare for patients; patient characteristics and ease of transport are determining factors for respondents when choosing an option for drug administration. We found OBI is the preferred alternative by most HCPs and a good resource optimization strategy in the context of cancer patients’ health care in Colombia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12913-023-09454-z. BioMed Central 2023-05-23 /pmc/articles/PMC10207821/ /pubmed/37221537 http://dx.doi.org/10.1186/s12913-023-09454-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Larrarte-González, María Alejandra
Pineda-Posada, Mariana
Gaitán, Álvaro Andrés
Amaya-Amaya, Jenny
Ojeda, Kelman
Health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia
title Health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia
title_full Health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia
title_fullStr Health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia
title_full_unstemmed Health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia
title_short Health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia
title_sort health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in colombia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207821/
https://www.ncbi.nlm.nih.gov/pubmed/37221537
http://dx.doi.org/10.1186/s12913-023-09454-z
work_keys_str_mv AT larrartegonzalezmariaalejandra healthprofessionalspreferenceswiththeuseofpegfilgrastimonbodyinjectoratoncologycentersin8citiesincolombia
AT pinedaposadamariana healthprofessionalspreferenceswiththeuseofpegfilgrastimonbodyinjectoratoncologycentersin8citiesincolombia
AT gaitanalvaroandres healthprofessionalspreferenceswiththeuseofpegfilgrastimonbodyinjectoratoncologycentersin8citiesincolombia
AT amayaamayajenny healthprofessionalspreferenceswiththeuseofpegfilgrastimonbodyinjectoratoncologycentersin8citiesincolombia
AT ojedakelman healthprofessionalspreferenceswiththeuseofpegfilgrastimonbodyinjectoratoncologycentersin8citiesincolombia